Christopher Maxwell
Family Medicine · Kansas City, MONPI 1740278464
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.2% of the total across 477 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 48 manufacturers, the largest accounting for just 14.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,874 and has fallen 98.6% since, to $26 in 2025. Among family medicine clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 477 payments — averaging $14.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$999
- AstraZeneca$888
- Novo Nordisk$527
- Boehringer Ingelheim$485
- Lilly USA, LLC$458
- Pfizer$348
- plus $3K from 42 others
What the payments were for
- Food & beverage$6,88598%
- Education$1302%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,015 in reported general payments places this provider in the 90th percentile of 2,203 family medicine providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 97 | $96,210 |
| MounjaroTirzepatide | 73 | $83,892 |
| OzempicSemaglutide | 50 | $64,443 |
| EliquisApixaban | 77 | $63,022 |
| XifaxanRifaximin | 12 | $42,748 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $28,090 |
| TrulicityDulaglutide | 20 | $25,568 |
| XareltoRivaroxaban | 25 | $24,424 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 34 | $23,195 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 108 | $22,993 |
| VraylarCariprazine Hcl | 13 | $21,825 |
| FarxigaDapagliflozin Propanediol | 26 | $21,337 |
| Xtampza ErOxycodone Myristate | 24 | $18,175 |
| MyrbetriqMirabegron | 31 | $14,619 |
| JanuviaSitagliptin Phosphate | 18 | $14,420 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $458 | $109,46093 claims |
| Boehringer IngelheimJardiance | $485 | $96,21097 claims |
| GSKTrelegy Ellipta, Shingrix, Breo Ellipta, Anoro Ellipta | $136 | $70,079165 claims |
| Novo NordiskOzempic | $527 | $64,44350 claims |
| PfizerEliquis | $348 | $63,02277 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Bevespi Aerosphere, Symbicort | $888 | $58,46799 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $208 | $42,74812 claims |
| Johnson & JohnsonXarelto | $165 | $24,42425 claims |
| AbbVieVraylar | $999 | $21,82513 claims |
| MerckJanuvia, Belsomra | $166 | $20,46033 claims |
| Collegium Pharmaceutical, Inc.Xtampza Er | $75 | $18,17524 claims |
| Astellas Pharma US IncMyrbetriq | $162 | $14,61931 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,203 family medicine providers in Missouri.
Other family medicine in Kansas City
- Blair ThedingerKansas City$71K
- Jon MattsonKansas City$53K
- Meredith LevineKansas City$26K
- Kelly SandriKansas City$17K
- Michael SimanovskyKansas City$16K
- Teresa MarshallKansas City$16K
- Nora GomezKansas City$15K
- Julie AlvarezKansas City$15K
- Neal MooreKansas City$14K
- Stephen AdamsSpringfield$636K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.